Pacritinib for KSHV-associated Castleman disease and KICS
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study tests a drug called pacritinib for people with KSHV-associated multicentric Castleman disease (MCD) or KSHV-associated inflammatory cytokine syndrome (KICS). It aims to see if the drug can help control symptoms and inflammation caused by these conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a confirmed diagnosis of KSHV-associated multicentric Castleman disease (MCD) or KSHV-associated inflammatory cytokine syndrome (KICS).
- You must have at least one symptom like fever, fatigue, stomach issues, or breathing problems related to your condition.
- You must have at least one abnormal lab result like low red blood cells (anemia), low platelets, low albumin, or high C-reactive protein (CRP).
- Your condition should not be life-threatening or causing severe organ damage right now.
- If you have HIV, you need to be on effective HIV medications (excluding certain drugs that interfere with the study drug).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks people with KICS, a condition caused by KSHV (a virus related to Kaposi sarcoma). It aims to understand the syndrome better and may lead to future treatments.
This study looks at how KSHV-associated multicentric Castleman disease naturally progresses over time, without necessarily testing a new treatment. It may help doctors better understand the disease and what changes to watch for, which could guide future care.
This trial tests the drug ruxolitinib for people with idiopathic multicentric Castleman disease (iMCD) whose symptoms are not well controlled by standard anti-IL-6 therapy. Ruxolitinib is a pill taken by mouth that may help reduce inflammation and improve symptoms.
This trial tests an experimental drug (CYT107) that boosts the immune system to help fight Kaposi sarcoma in people with HIV who have a low CD4 count despite good HIV treatment. It aims to see if the drug can improve KS tumors and quality of life.
This Phase 1/2 study tests PDS01ADC, a targeted cancer drug, for advanced Kaposi sarcoma (KS). It also studies how well the drug works when added to the immunotherapy M7824, especially if KS has not responded to prior treatments.
This study collects and analyzes tumor tissue to learn what drives certain cancers and growths linked to viruses, HIV, and immune system problems. Results may help researchers understand disease causes and point to better future treatments.
Hear when a new KSHV Inflammatory Cytokine Syndrome (KICS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.